CRISPR/Cas9 genome editing technology contributes to the expansion of the creation of novel disease model Tokyo, Japan, and Dublin, Ireland, March 13, 2024: Ricoh Company,…
License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness Dublin, Ireland, and Tampere, Finland,…
· Patent JP6692856 upheld for second time in response to invalidation challenge Dublin, Ireland, 13 December 2023: ERS Genomics Limited, which was formed to…
New licence provides CHUM access to the ERS CRISPR/Cas9 patent portfolio. DUBLIN and MONTREAL, Oct. 26, 2023 /PRNewswire/ — ERS Genomics Limited (‘ERS’) is pleased to announce a new…
Dublin, Ireland – 19/10/2023** – ERS Genomics Limited (‘ERS’) completes licensing agreement with Syngene International, India’s leading Contract Research, Development and Manufacturing Organization. Syngene gains…
ERS Genomics & Demeetra Enter Into CRISPR/Cas9 Licensing Agreement Demeetra to broaden synthetic biology and bioprocessing technology through combined CRISPR/Cas9 IP and Demeetra’s own dimeric…
ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement License allows AlgenScribe to expand its research and development activities using CRISPR/Cas9. Dublin, Ireland and Nice,…
License allows Santa Cruz Biotechnology to develop and commercialize products using CRISPR/Cas9. Dublin, Ireland and Dallas, Texas, 10 August 2023: ERS Genomics Limited (‘ERS’) is…